Your browser doesn't support javascript.
loading
Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy.
Sarrett, Samantha M; Keinänen, Outi; Dayts, Eric J; Dewaele-Le Roi, Guillaume; Rodriguez, Cindy; Carnazza, Kathryn E; Zeglis, Brian M.
Afiliação
  • Sarrett SM; Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.
  • Keinänen O; PhD Program in Biochemistry, Graduate Center of the City University of New York, New York, NY, USA.
  • Dayts EJ; Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.
  • Dewaele-Le Roi G; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rodriguez C; Department of Chemistry, Radiochemistry, University of Helsinki, Helsinki, Finland.
  • Carnazza KE; Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.
  • Zeglis BM; Department of Chemistry, Hunter College, City University of New York, New York, NY, USA.
Nat Protoc ; 16(7): 3348-3381, 2021 07.
Article em En | MEDLINE | ID: mdl-34127865
Radiolabeled antibodies have shown promise as tools for both the nuclear imaging and endoradiotherapy of cancer, but the protracted circulation time of radioimmunoconjugates can lead to high radiation doses to healthy tissues. To circumvent this issue, we have developed an approach to positron emission tomography (PET) imaging and radioimmunotherapy (RIT) predicated on radiolabeling the antibody after it has reached its target within the body. This in vivo pretargeting strategy is based on the rapid and bio-orthogonal inverse electron demand Diels-Alder reaction between tetrazine (Tz) and trans-cyclooctene (TCO). Pretargeted PET imaging and RIT using TCO-modified antibodies in conjunction with Tz-bearing radioligands produce high activity concentrations in target tissues as well as reduced radiation doses to healthy organs compared to directly labeled radioimmunoconjugates. Herein, we describe how to prepare a TCO-modified antibody (humanized A33-TCO) as well as how to synthesize two Tz-bearing radioligands: one labeled with the positron-emitting radiometal copper-64 ([64Cu]Cu-SarAr-Tz) and one labeled with the ß-emitting radiolanthanide lutetium-177 ([177Lu]Lu-DOTA-PEG7-Tz). We also provide a detailed description of pretargeted PET and pretargeted RIT experiments in a murine model of human colorectal carcinoma. Proper training in both radiation safety and the handling of laboratory mice is required for the successful execution of this protocol.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioimunoterapia / Tomografia por Emissão de Pósitrons / Elétrons / Química Click / Reação de Cicloadição Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nat Protoc Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioimunoterapia / Tomografia por Emissão de Pósitrons / Elétrons / Química Click / Reação de Cicloadição Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nat Protoc Ano de publicação: 2021 Tipo de documento: Article